Apremilast for Erythema Multiforme — AEM  

Erythema Multiforme Clinical Trial

Official title: Apremilast for the Treatment of Refractory Erythema Multiforme

Status Recruiting

Clinical Trial Summary

This study is recruiting patients with chronic, treatment resistant erythema multiforme (EM), which is a disease that can affect the skin and mucous membranes (mucocutaneous). EM often impacts quality of life with pain, anorexia, hospitalization, and related long-term issues. While there are medications used to treat EM, no single therapeutic agent has been consistently effective for long-term management of disease. Apremilast (trade name: Otezla) is approved to treat Bechet's Disease, a different but similar mucocutaneous disease. In this study, eligible patients will receive apremilast for 6 months of treatment so we can evaluate if there is a difference in pain and the number of EM flares compared to prior to treatment with apremilast.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Erythema
• Erythema Multiforme

• NCT number: NCT05875714
• Study type: Interventional
• Source: University of Pennsylvania
• Contact: Joshua S Bryer, BA
• Phone: 215-662-6597
• Email: jbryer@pennmedicine.upenn.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: January 13, 2022
• Completion date: December 31, 2024